BioSpace News Archive

Business

NexImmune Announces Melanoma Research Collaboration with NYU Langone’s Perlmutter Cancer Center

NexImmune, Inc. today announced a research and evaluation collaboration with The Laura and Isaac Perlmutter Cancer Center, a National Cancer Institute designated Comprehensive Cancer Center and part of NYU Langone Health.

March 14, 2022
·
4 min read
Business

Gracell Biotechnologies Reports Fourth Quarter and Full Year 2021 Unaudited Financial Results and Provides Corporate Update

Gracell Biotechnologies Inc. today reported fourth quarter and full year unaudited financial results for the period ended December 31, 2021, and provided corporate updates.

March 14, 2022
·
13 min read
Drug Development

BridgeBio Pharma Announces Positive Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)

BridgeBio Pharma, Inc. today announced positive data from the Phase 2 study of BBP-418 in patients with limb-girdle muscular dystrophy type 2i (LGMD2i).

March 14, 2022
·
9 min read
Drug Development

Abeona Therapeutics Achieves Target Enrollment in Pivotal Phase 3 VIITAL™ Study of EB-101 in RDEBTopline data from VIITAL™ expected in the third quarter of 2022

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that target enrollment has been achieved in its pivotal Phase 3 VIITAL™ study.

March 14, 2022
·
6 min read
Business

Miravo Healthcare™ Announces Fourth Quarter 2021 Results Release Date and Conference Call Details

Miravo Healthcare ™ Announces Fourth Quarter 2021 Results Release Date and Conference Call Details.

March 14, 2022
·
1 min read
Lone Star Bio

Enzolytics, Inc.'s Wholly Owned Subsidiary Virogentics, Inc. Reports Progress on the Delivery of its ITV-1 Anti-HIV Therapeutic for Use by Patients in African Regions

Enzolytics, Inc. today announced its progress toward the production and use of its ITV-1, anti-HIV immunotherapy treatment in the Central and Eastern regions of Africa for patients with HIV/AIDS.

March 14, 2022
·
5 min read
Biotech Bay

Seer Announces Publication of Seminal Study Demonstrating Superior Performance of Technology Platform for Deep, Unbiased, Precise, Scalable Proteomics in the Proceedings of the National Academy of Sciences

Seer, Inc. announced the publication of a study demonstrating the performance of the technology platform underlying the Proteograph Product Suite™ for deep, unbiased, precise, scalable proteomics.

March 14, 2022
·
5 min read
Genetown

Fulcrum Therapeutics® Presents Data Highlighting Reachable Workspace (RWS) as Relevant Functional Endpoint in Facioscapulohumeral Muscular Dystrophy (FSHD) at MDA Clinical and Scientific Conference

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced data demonstrating that Reachable Workspace (RWS) is a quantitative and relevant measurement of function that can be used to assess disease progression as well as response to treatment in people with facioscapulohumeral muscular dystrophy (FSHD).

March 14, 2022
·
8 min read
Business

Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 17th

Avadel Pharmaceuticals plc announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 17, 2022, to provide a corporate update and discuss the Company’s financial results for the fourth quarter and full year ended December 31, 2021.

March 14, 2022
·
1 min read
Business

Adaptimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update

Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update.

March 14, 2022
·
15 min read